Cargando…
Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847092/ https://www.ncbi.nlm.nih.gov/pubmed/35181372 http://dx.doi.org/10.1016/j.jinf.2022.02.009 |
| _version_ | 1784651974790086656 |
|---|---|
| author | Tré-Hardy, Marie Cupaiolo, Roberto Wilmet, Alain Antoine-Moussiaux, Thomas Coman-Vlagea, Nicoleta Della Vecchia, Andrea Horeanga, Alexandra Papleux, Emmanuelle Vekemans, Marc Beukinga, Ingrid Blairon, Laurent |
| author_facet | Tré-Hardy, Marie Cupaiolo, Roberto Wilmet, Alain Antoine-Moussiaux, Thomas Coman-Vlagea, Nicoleta Della Vecchia, Andrea Horeanga, Alexandra Papleux, Emmanuelle Vekemans, Marc Beukinga, Ingrid Blairon, Laurent |
| author_sort | Tré-Hardy, Marie |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8847092 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88470922022-02-16 Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected Tré-Hardy, Marie Cupaiolo, Roberto Wilmet, Alain Antoine-Moussiaux, Thomas Coman-Vlagea, Nicoleta Della Vecchia, Andrea Horeanga, Alexandra Papleux, Emmanuelle Vekemans, Marc Beukinga, Ingrid Blairon, Laurent J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-04 2022-02-16 /pmc/articles/PMC8847092/ /pubmed/35181372 http://dx.doi.org/10.1016/j.jinf.2022.02.009 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Tré-Hardy, Marie Cupaiolo, Roberto Wilmet, Alain Antoine-Moussiaux, Thomas Coman-Vlagea, Nicoleta Della Vecchia, Andrea Horeanga, Alexandra Papleux, Emmanuelle Vekemans, Marc Beukinga, Ingrid Blairon, Laurent Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected |
| title | Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected |
| title_full | Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected |
| title_fullStr | Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected |
| title_full_unstemmed | Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected |
| title_short | Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected |
| title_sort | assessment 2 months after the administration of a 3rd dose mrna: a new variant-adapted vaccine is expected |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847092/ https://www.ncbi.nlm.nih.gov/pubmed/35181372 http://dx.doi.org/10.1016/j.jinf.2022.02.009 |
| work_keys_str_mv | AT trehardymarie assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected AT cupaioloroberto assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected AT wilmetalain assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected AT antoinemoussiauxthomas assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected AT comanvlageanicoleta assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected AT dellavecchiaandrea assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected AT horeangaalexandra assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected AT papleuxemmanuelle assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected AT vekemansmarc assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected AT beukingaingrid assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected AT blaironlaurent assessment2monthsaftertheadministrationofa3rddosemrnaanewvariantadaptedvaccineisexpected |